Table 2.
Anti-infective mAb in clinical trial developmenta.
| Name (type) | Target | Clinical trials phase | |
|---|---|---|---|
| Virus | |||
| RSV | Palivizumab (humanized mAb) | Glycoprotein F | Approved |
| Motavizumab (humanized mAb) | Glycoprotein F | I–III | |
| HIV | CCR5mAb004 (human mAb) | CCR5 | I |
| PRO 140 (humanized mAb) | CCR5 | II | |
| 3 mAb cocktail | I/II | ||
| F105 (human mAb) | gp120 | I | |
| Ibalizumab (humanized mAb) | CD4 | II | |
| CMV | Sevirumab (human mAb) | Envelope glycoprotein H | II, III |
| HCV | Bavituximab (chimeric mAb) | Phosphatidylserine | Ib |
| MDX1106 (human mAb) | PD-1 | I | |
| Rabies | CL184 (mAb cocktail) | I | |
| WNV | MGAWN1 (humanized mAb) | Envelope glycoprotein | I |
| Bacteria/toxin | |||
| E. coli | Urtoxazumab (humanized mAb) | Shiga-like toxin 2B | |
| C. difficile | GS-CDA1 (human mAb) | C. difficile toxin A | II |
| MDX-388 (human mAb) | C. difficile toxin B | II | |
| Staphylococcus | Pagibaximab (chimeric mAb) | LTA | II |
| Tefibazumab (humanized mAb) | Clumping factor A | II | |
| B. anthracis | Anthim | PA | I |
| Raxibacumab | PA | III | |
| Fungal | |||
| C. neoformans | 18B7 (murine mAb) | Capsular polysaccharide | I |
a
Source: http://clinicaltrials.gov/ (not a complete list).